BioSpace News Archive

ElevateBio, a Cambridge-based cell and gene therapy holding company, today announced that Melissa K. Carpenter, Ph.D., has been appointed to the newly created position of Chief Scientific Officer of Regenerative Medicine

The American Cancer Society (ACS) announces three new members and the newly-elected leadership officers to the Board of Directors, with all terms beginning on January 1, 2020.

Vitruvian Partners leads a $63.4 million equity round, complemented by $21.2 million in new, non-dilutive grant funding and loans to further support commercialization efforts

Galderma announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to the investigational therapy nemolizumab for the treatment of pruritus associated with prurigo nodularis..

A pilot study published in the Breast Journal shows the benefits of using Endermologie - a trademark of LPG SYSTEMS - in breast reconstruction after mastectomy and radiotherapy.

Epidarex’s therapeutic discovery engine will identify innovative early stage assets, providing hands-on scientific support and funding to drive drug discovery projects

Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, is pleased to announce that it plans to conduct its first phase 2 clinical trial of its repurposed drug NP-120 for patients with idiopathic pulmonary fibrosis and chronic cough.

Aurinia Pharmaceuticals Inc., a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced that it has commenced a registered underwritten public offering of US$150,000,000 of its common shares.

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, prostate and colorectal, today announced the presentation of final results from the Company’s Phase 1b study of onvansertib in patients with relapsed/refractory acute myeloid leukemia (AML)

Clinical trials are an essential gateway for getting new cures to market. However, many patients struggle to find the right trials that meet their unique medical requirements.